Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary

• Cue Biopharma Inc CUE reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -38 cents. The mean expectation of five analysts for the quarter was for a loss of 28 cents per share. Wall Street expected results to range from -34 cents to -23 cents per share.

• Revenue rose 1,106% to $1.82 million from a year ago; analysts expected $1.57 million.

• Cue Biopharma Inc's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $13.43 million.

• Cue Biopharma Inc shares had fallen by 30.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Cue Biopharma Inc is $8.00

This summary was machine generated from LSEG data March 28 at 10:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)